Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.
Biocon Biologics and Sandoz have struck a marketing partnership in Australia that will see Sandoz commercialize Biocon’s Ogivri (trastuzumab) and Abevmy (bevacizumab) biosimilars.
The five-year deal will give Sandoz exclusive rights to promote, sell and distribute the trastuzumab and bevacizumab biosimilars – which...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
